Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro successfully implanted the first WATCHMAN FLX Pro Device on April 1. MCH ...

Boston Scientific, Inc. BSX recently announced receiving the FDA approval for the latest-generation WATCHMAN FLX Pro Left Atrial Appendage Closure (LAAC) Device. The latest device is intended to ...

The WATCHMAN FLX Pro team (pictured here) has successfully completed 159 WATCHMAN procedures, and will now only use the updated WATCHMAN FLX Pro Device moving forward. (Courtesy Photo) Medical Center ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

After the FDA said last year it would keep a closer eye on the potential complications of a type of permanent heart plug designed to cut the risk of stroke, Boston Scientific has put forward ...

Left atrial appendage (LAA) closure with the new-generation Watchman FLX device (Boston Scientific) provides a high rate of effective closure with few early adverse events, according to results of ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

A Watchman is a device that can help prevent blood clots from leaving the heart. However, the procedure to insert the device carries its risks, including cardiac tamponade and ischemic stroke. The ...